Navelbine (Vinorelbine)

Vinorelbine interferes with microtubule assembly by binding to tubulin, preventing the formation of the mitotic spindle. This halts cell division at the M phase, leading to programmed cell death of rapidly dividing cancer cells.

The specific dose of Navelbine is determined by the treating oncologist based on the patient’s cancer type, stage, overall health, and other concurrent therapies. Only a qualified prescriber can set the appropriate regimen.

Safety data for vinorelbine in pregnancy and lactation are limited, and the product is generally contraindicated. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative options with their healthcare provider.

To request Navelbine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Vinorelbine shares the microtubule‑targeting mechanism of other Vinca alkaloids such as vincristine and vinblastine, but it is formulated for oral administration and has a distinct toxicity profile, often showing lower neurotoxicity but higher rates of neutropenia.

Navelbine oral capsules should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container, protect from moisture and direct sunlight, and ensure the packaging remains sealed until use.

Navelbine is taken orally as a capsule with water, usually on an empty stomach or as directed by the prescribing physician. The exact timing relative to meals and other medications is determined by the treatment protocol.

The most critical risks include severe neutropenia or febrile neutropenia, pulmonary toxicity such as interstitial pneumonitis, and rare but serious allergic reactions. Patients should be monitored closely for signs of infection, breathing difficulties, or rash.

Navelbine is contraindicated in patients with known hypersensitivity to vinorelbine or any Vinca alkaloid, in those with severe bone‑marrow suppression, and in individuals with uncontrolled infections or significant hepatic impairment unless specifically advised by a specialist.